Literature DB >> 19894472

Reactive localised inflammatory hyperplasia of the oral mucosa.

D O Awange1, K A Wakoli, J F Onyango, M L Chindia, E O Dimba, S W Guthua.   

Abstract

OBJECTIVE: To document the histopathological pattern and distribution of reactive localised inflammatory hyperplastic lesions of the oral mucosa diagnosed at the University of Nairobi Dental Hospital over a 14 year period.
DESIGN: A retrospective, cross-sectional descriptive study.
SETTING: Division of Oral Pathology and Oral Medicine, histopathology laboratory, School of Dental Sciences, University of Nairobi.
SUBJECTS: A total of 3135 oral biopsies were accessioned in the oral diagnostic histopathological Laboratory registry over a period of 14 years from March 1991 to December 2005.
RESULTS: Three hundred and thirty three cases were histopathologically diagnosed as reactive inflammatory hyperplasias of the oral mucosa. This constituted 10.6% of the total oral biopsy specimens analysed during this period. Fibrous epulis was the most common histological sub-type with 129 cases (38.7%) followed by pyogenic granuloma with 94 (28.3%) cases. Six (1.8%) cases were peripheral giant cell granuloma and three cases (0.9%) were those of denture irritation hyperplasia. The age distribution ranged from 2 to 78 years (mean = 30.5 years) with a peak at 20-29 years. Gender distribution showed that 107 (32%) cases occurred in males and 226 (68%) cases females. Similar trends were observed in most of the histological sub-types. Fibrous epulis occurred in 41 male (31.8%) cases and in 88 (68.2%) females with an age range of 2 to 78 years (mean = 30.5 years). As for the pyogenic granuloma, 26 (27.7%) lesions occurred in males and 68 (72.3%) in females with an age range of 2 to 75 years (mean = 30.1 years). Among all the histopathological sub-types it was shown that 223 (67.0%) cases were fibrous, 104 (31.2%) vascular and six (1.8%) peripheral giant cell granuloma. Gingival lesions were the most common with 257 (77.2%) cases followed by 28 (8.4%) in the tongue, 16 (4.8%) lips, 15 (4.5%) cheek, six (1.8%) palate and the rest on the floor of the mouth and other mucosal sites. The duration of these lesions was recorded in 182 (54.7%) cases and ranged from 1 week to 16 years (mean = 1.8 years). Only 15 (4.5%) cases were reported to have recurred and all of them were gingival lesions.
CONCLUSION: The present study has shown that the prevalence of reactive localised inflammatory hyperplasia (RLIHs) of the oral mucosa was 10.6% with fibrous epulis and pyogenic granuloma having been the most common histopathological sub-types predominantly affecting females. Although RLIHs are distinguished on clinical or histopatholocal grounds, it is important to appreciate that they are variations of the same basic process.

Entities:  

Mesh:

Year:  2009        PMID: 19894472     DOI: 10.4314/eamj.v86i2.46939

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  5 in total

1.  Identification of HPV16-p16INK4a mediated methylation in oral potentially malignant disorder.

Authors:  Maria Rosa Buenahora; Gloria Inés Lafaurie; Sandra J Perdomo
Journal:  Epigenetics       Date:  2020-11-09       Impact factor: 4.528

2.  Assessment of reactive gingival lesions of oral cavity: A histopathological study.

Authors:  Santosh Hunasgi; Anila Koneru; M Vanishree; Vardendra Manvikar
Journal:  J Oral Maxillofac Pathol       Date:  2017 Jan-Apr

3.  Reactive lesions of the oral cavity: A retrospective study on 2068 cases.

Authors:  Noushin Jalayer Naderi; Nosratollah Eshghyar; Hora Esfehanian
Journal:  Dent Res J (Isfahan)       Date:  2012-05

4.  Reactive hyperplastic lesions of the oral cavity: A ten year observational study on North Indian Population.

Authors:  Vandana Reddy; Susmita Saxena; Sanjeev Saxena; Munish Reddy
Journal:  J Clin Exp Dent       Date:  2012-07-01

5.  Massive fibrous epulis-a case report of a 10-year-old lesion.

Authors:  Gabriel M Fonseca; Ricardo M Fonseca; Mario Cantín
Journal:  Int J Oral Sci       Date:  2013-10-18       Impact factor: 6.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.